Olbas inhaler

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Cajuput oil; Peppermint oil; Levomenthol; Eucalyptus oil

Disponible depuis:

G.R. Lane Health Products Ltd

Code ATC:

R05X

DCI (Dénomination commune internationale):

Cajuput oil; Peppermint oil; Levomenthol; Eucalyptus oil

Dosage:

200mg/1gram ; 200mg/1gram ; 400mg/1gram ; 200mg/1gram

forme pharmaceutique:

Inhalation vapour

Mode d'administration:

Nasal

classe:

No Controlled Drug Status

Type d'ordonnance:

Never Valid To Prescribe As A VMP

Descriptif du produit:

BNF: 12020200; GTIN: 5000477233968 5000477977091

Notice patient

P
U
R
E
P
L
A
N
T
O
I
L
S
P
U
R
E
P
L
A
N
T
O
I
L
S
C
O
N
T
A
I
N
S
The pure plant remedy for symptomatic relief of blocked sinuses,
catarrh, hay fever, colds and flu. Olbas Inhaler contains essential
oils that have decongestant properties.
Before you use Olbas Inhaler.
Do not use if you are allergic to any of the ingredients.
Taking other medicines Please tell your doctor or pharmacist if you
are
taking or have recently taken any other medicines, including medicines
obtained without a prescription. Pregnancy and breast-feeding It is
best
not to take any non-essential medication when pregnant or
breast-feeding.
Ask your doctor or pharmacist for advice before taking any medicine.
How to use Olbas Inhaler
Adults and children aged 6 and over: Unscrew outer cover from base
of stick, close one nostril, place inhaler in other nostril, and
inhale deeply.
After use, wipe stick with a tissue and replace cover. Not recommended
for children under 6 years old. Do not use more than 4 times an hour.
If you use more Olbas Inhaler than you should, talk to a doctor or
pharmacist.
You must contact a doctor if symptoms worsen or do not improve after 7
days.
Possible side effects
Like all medicines, Olbas Inhaler can cause side effects although not
everybody gets them. May cause allergic reactions such as rash.
If you notice any side effect, please tell your doctor or pharmacist.
How to store Olbas Inhaler
Keep out of the reach and sight of children. Do not use Olbas Inhaler
after
the expiry date which is stated on the packaging. Do not store above
25°C.
Further information
Active ingredients w/w: Cajuput Oil 20%, Eucalyptus Oil 20%,
Levomenthol 40%, Peppermint Oil 20%.
Manufactured by the Marketing Authorisation holder:
G. R. Lane Health Products Ltd., Sisson Road,
Gloucester, GL2 0GR, UK.
NASAL STICK
NASAL STICK
_inhaler_
_inhaler_
_inhaler_
_inhaler_
Relief from catarrh, colds
and blocked sinuses
_Olbas_
_Olbas_
_Olbas_
_Olbas_
5000477233968
695mg
PL 1074/0003
Approved:
July 2008
380034
P
U
R
E
P
L
A
N
T
O
I
L
S
P
U
R
E
P
L
A
N

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Olbas Inhaler Nasal Stick
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Ingredients
%w/w
Cajuput Oil
20
Levomenthol
40
Peppermint Oil
20
Eucalyptus Oil
20
3
PHARMACEUTICAL FORM
Nasal stick.
White tube closed with a white cap and containing a wad dosed with
Olbas
Inhaler oil.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For the symptomatic relief of blocked up sinuses, catarrh, hay fever,
colds and
influenza.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
For nasal use.
Adults and children aged 6 and over: Insert into each nostril in turn
and inhale
whilst keeping the other nostril closed. Do not use more than four
times per
hour.
Not recommended for children under 6 years old.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substances.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
If symptoms worsen or do not improve after 7 days, a doctor should be
contacted.
4.5
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
No interaction studies have been performed.
4.6
PREGNANCY AND LACTATION
There are no or limited amount of data from the use of Olbas Inhaler
in
pregnant women. Animal studies are insufficient with respect to
reproductive
toxicity. Olbas Inhaler should not be used during pregnancy unless
potential
benefits outweigh any risks.
It is unknown whether Olbas Inhaler/metabolites are excreted in human
or
animal milk. However, at therapeutic doses of Olbas Inhaler no effects
on the
breastfed
newborns/infants
are
anticipated.
Nevertheless
it
is
not
recommended that Olbas Inhaler be used during breast feeding.
4.7
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
Olbas Inhaler has no influence on the ability to drive and use
machines.
4.8
UNDESIRABLE EFFECTS
No
undesirable
effects
are
likely
with
this
product
because
of
the
low
concentrations
of
the
active
ingredients.
However,
local
hypersensitivity,
contact
dermatitis
and
irritant
effects
of
Levomenthol
are
listed
in
the
literature.
4.9.
OVERDOSE
Reports of an overdose by inha